BRS 001

Drug Profile

BRS 001

Alternative Names: Cancer vaccine - Therapeutic Solutions

Latest Information Update: 14 Jun 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Therapeutic Solutions International
  • Class Cancer vaccines; Dendritic cell vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I Cancer
  • Preclinical Solid tumours

Most Recent Events

  • 31 May 2018 Pan American Cancer Treatment Center in-licenses StemVacs immunotherapy platform technology from Therapeutics Solutions International
  • 31 May 2018 Phase-I clinical trials in Cancer in Mexico (Parenteral) before May 2018
  • 12 Apr 2017 StemVacs licensed to Emvolio worldwide
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top